OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Visco on Next Steps for the MANTLE-FIRST Trial in Relapsed/Refractory MCL

September 17th 2020

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Dr. Bose on Novel Agents Under Investigation in Essential Thrombocythemia

September 17th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Dr. Trinh on Prostate Cancer Treatment During the COVID-19 Crisis

September 17th 2020

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

Dr. Deol on the Approval of Brexucabtagene Autoleucel in MCL

September 17th 2020

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

September 17th 2020

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma

September 17th 2020

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Dr. Nguyen on the Utility of a Brachytherapy Boost in the ASCENDE-RT Trial

September 16th 2020

Paul L. Nguyen, MD, discusses the utility of adding a brachytherapy boost to radiation therapy in the ASCENDE-RT trial.

Dr. Leslie on the Need for Clinical Trials to Address Unmet Needs in MCL

September 16th 2020

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Dr. Alkharabsheh on Novel Agents Under Exploration in Myelofibrosis

September 16th 2020

Omar Alkharabsheh, MD, discusses novel agents under exploration in the field of myelofibrosis.

Dr. Ocean on the Development of Nanoliposomal Irinotecan in Metastatic Pancreatic Cancer

September 16th 2020

Allyson Ocean, MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer.

Dr. Farrington on the Importance of Patient Advocacy in CRC

September 16th 2020

Caroline Farrington, PhD, discusses the importance of patient advocacy in colorectal cancer.

Dr. Shoushtari on the Role of Nivolumab and Ipilimumab in Mucosal Melanoma

September 16th 2020

Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma.

Dr. Maddocks on Unanswered Questions With BTK Inhibitors in B-Cell Malignancies

September 16th 2020

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

Dr. Burke on Treatment Options in Low-Tumor Burden Follicular Lymphoma

September 16th 2020

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

Dr. Pagel on the Evolution of Treatment in DLBCL

September 16th 2020

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Dr. Kahl on the Current Treatment Landscape in Relapsed/Refractory iNHL

September 15th 2020

Brad S. Kahl, MD, discusses the current treatment landscape in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Johnson on the Need for Novel Biomarkers in Melanoma

September 15th 2020

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Dr. McGregor on Future Research in mCRPC

September 15th 2020

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCC

September 15th 2020

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Dr. Motzer on the TIVO-1 Trial With Tivozanib in Advanced RCC

September 15th 2020

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.